Tags

Type your tag names separated by a space and hit enter

Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study.
J Am Heart Assoc. 2014 Sep 18; 3(5):e001082.JA

Abstract

BACKGROUND

Increased concentrations of circulating fibroblast growth factor 23 (FGF-23) have been associated with higher risk of cardiovascular disease. The association between FGF-23 and the risk of atrial fibrillation (AF), a common arrhythmia, is less defined. Thus, we explored whether FGF-23 concentration was associated with AF incidence in a large community-based cohort.

METHODS AND RESULTS

We studied 12 349 men and women enrolled in the Atherosclerosis Risk in Communities (ARIC) study, without prevalent AF at baseline in 1990-1992. Serum intact FGF-23 concentration was measured with the Kainos 2-site ELISA. Incident AF through 2010 was ascertained from study ECGs and hospital discharge codes. Cox proportional hazards models adjusted for potential confounding factors, including kidney function, were used to estimate the association between FGF-23 and AF risk. We identified 1572 AF events during a mean follow-up of 17 years. In multivariable analysis, a difference of 1 SD (16 pg/mL) in baseline FGF-23 was not associated with the risk of AF (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.99, 1.09). Results were similar when FGF-23 was modeled in quartiles (HR, 1.09; 95% CI, 0.94, 1.26, comparing extreme quartiles). Reduced kidney function was associated with increased AF risk across quartiles of FGF-23 levels.

CONCLUSION

In this large community-based cohort, baseline FGF-23 levels were not associated with AF risk independently of kidney function. Our results do not support a major role for FGF-23 as a risk factor for AF or as a mediator of the association between chronic kidney disease and AF.

Authors+Show Affiliations

Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN (A.A., J.R.M., P.L.L.).Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN (A.A., J.R.M., P.L.L.).Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN (J.H.E.).Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S., J.C., S.K.A.).Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S., J.C., S.K.A.).Division of Cardiovascular Sciences, University of Minnesota Medical School, Minneapolis, MN (L.Y.C.).Epidemiological Cardiology Research Center, Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC (E.Z.S.).Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S., J.C., S.K.A.).Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN (A.A., J.R.M., P.L.L.).

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25237047

Citation

Alonso, Alvaro, et al. "Circulating Fibroblast Growth Factor-23 and the Incidence of Atrial Fibrillation: the Atherosclerosis Risk in Communities Study." Journal of the American Heart Association, vol. 3, no. 5, 2014, pp. e001082.
Alonso A, Misialek JR, Eckfeldt JH, et al. Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. J Am Heart Assoc. 2014;3(5):e001082.
Alonso, A., Misialek, J. R., Eckfeldt, J. H., Selvin, E., Coresh, J., Chen, L. Y., Soliman, E. Z., Agarwal, S. K., & Lutsey, P. L. (2014). Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. Journal of the American Heart Association, 3(5), e001082. https://doi.org/10.1161/JAHA.114.001082
Alonso A, et al. Circulating Fibroblast Growth Factor-23 and the Incidence of Atrial Fibrillation: the Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2014 Sep 18;3(5):e001082. PubMed PMID: 25237047.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. AU - Alonso,Alvaro, AU - Misialek,Jeffrey R, AU - Eckfeldt,John H, AU - Selvin,Elizabeth, AU - Coresh,Josef, AU - Chen,Lin Y, AU - Soliman,Elsayed Z, AU - Agarwal,Sunil K, AU - Lutsey,Pamela L, Y1 - 2014/09/18/ PY - 2014/9/20/entrez PY - 2014/9/23/pubmed PY - 2015/11/18/medline KW - atrial fibrillation KW - epidemiology KW - kidney KW - risk factors SP - e001082 EP - e001082 JF - Journal of the American Heart Association JO - J Am Heart Assoc VL - 3 IS - 5 N2 - BACKGROUND: Increased concentrations of circulating fibroblast growth factor 23 (FGF-23) have been associated with higher risk of cardiovascular disease. The association between FGF-23 and the risk of atrial fibrillation (AF), a common arrhythmia, is less defined. Thus, we explored whether FGF-23 concentration was associated with AF incidence in a large community-based cohort. METHODS AND RESULTS: We studied 12 349 men and women enrolled in the Atherosclerosis Risk in Communities (ARIC) study, without prevalent AF at baseline in 1990-1992. Serum intact FGF-23 concentration was measured with the Kainos 2-site ELISA. Incident AF through 2010 was ascertained from study ECGs and hospital discharge codes. Cox proportional hazards models adjusted for potential confounding factors, including kidney function, were used to estimate the association between FGF-23 and AF risk. We identified 1572 AF events during a mean follow-up of 17 years. In multivariable analysis, a difference of 1 SD (16 pg/mL) in baseline FGF-23 was not associated with the risk of AF (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.99, 1.09). Results were similar when FGF-23 was modeled in quartiles (HR, 1.09; 95% CI, 0.94, 1.26, comparing extreme quartiles). Reduced kidney function was associated with increased AF risk across quartiles of FGF-23 levels. CONCLUSION: In this large community-based cohort, baseline FGF-23 levels were not associated with AF risk independently of kidney function. Our results do not support a major role for FGF-23 as a risk factor for AF or as a mediator of the association between chronic kidney disease and AF. SN - 2047-9980 UR - https://www.unboundmedicine.com/medline/citation/25237047/Circulating_fibroblast_growth_factor_23_and_the_incidence_of_atrial_fibrillation:_the_Atherosclerosis_Risk_in_Communities_study_ L2 - https://www.ahajournals.org/doi/10.1161/JAHA.114.001082?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -